Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple autoimmune syndromes and overlap syndromes): A challenge for the autoimmunologist

Renato Tozzoli, Maria Concetta Sorrentino, Nicola Bizzaro

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In the last 15 years, the estimated prevalence of autoimmune diseases increased from about 4 to 9.4 %. Autoimmune co-morbidity (i.e., the association between two or more autoimmune diseases in the same patient) is present in 0.4-0.5 % of the worldwide population, more frequently in patients with multiple sclerosis, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease and vitiligo. The most common associations between autoimmune diseases define two clusters: the multiple autoimmune syndromes and overlap syndromes. This review highlights the importance of multiple antibody assays in the diagnosis of multiple autoimmune and overlap syndromes and summarizes the general conditions of autoantibody detection using the model of the five W's: why, who, what, when and where. These conditions represent a new challenge for clinical and laboratory autoimmunologists, who, in a multidisciplinary arena, cooperate in investigating and treating multiple autoimmune disorders.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalImmunologic Research
Volume56
Issue number2-3
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Autoantibodies
Autoimmune Diseases
Morbidity
Vitiligo
Thyroid Diseases
Type 1 Diabetes Mellitus
Inflammatory Bowel Diseases
Multiple Sclerosis
Rheumatoid Arthritis
Antibodies
Population

Keywords

  • Autoimmune liver diseases
  • Autoimmunology
  • Co-morbidity
  • Connective tissue diseases
  • Multiple autoimmune syndromes
  • Overlap syndromes
  • Polyautoimmunity

ASJC Scopus subject areas

  • Immunology

Cite this

@article{a5c30d6a90b2455aaa6d5a7b4b598ea8,
title = "Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple autoimmune syndromes and overlap syndromes): A challenge for the autoimmunologist",
abstract = "In the last 15 years, the estimated prevalence of autoimmune diseases increased from about 4 to 9.4 {\%}. Autoimmune co-morbidity (i.e., the association between two or more autoimmune diseases in the same patient) is present in 0.4-0.5 {\%} of the worldwide population, more frequently in patients with multiple sclerosis, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease and vitiligo. The most common associations between autoimmune diseases define two clusters: the multiple autoimmune syndromes and overlap syndromes. This review highlights the importance of multiple antibody assays in the diagnosis of multiple autoimmune and overlap syndromes and summarizes the general conditions of autoantibody detection using the model of the five W's: why, who, what, when and where. These conditions represent a new challenge for clinical and laboratory autoimmunologists, who, in a multidisciplinary arena, cooperate in investigating and treating multiple autoimmune disorders.",
keywords = "Autoimmune liver diseases, Autoimmunology, Co-morbidity, Connective tissue diseases, Multiple autoimmune syndromes, Overlap syndromes, Polyautoimmunity",
author = "Renato Tozzoli and Sorrentino, {Maria Concetta} and Nicola Bizzaro",
year = "2013",
month = "7",
doi = "10.1007/s12026-013-8418-7",
language = "English",
volume = "56",
pages = "425--431",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple autoimmune syndromes and overlap syndromes)

T2 - A challenge for the autoimmunologist

AU - Tozzoli, Renato

AU - Sorrentino, Maria Concetta

AU - Bizzaro, Nicola

PY - 2013/7

Y1 - 2013/7

N2 - In the last 15 years, the estimated prevalence of autoimmune diseases increased from about 4 to 9.4 %. Autoimmune co-morbidity (i.e., the association between two or more autoimmune diseases in the same patient) is present in 0.4-0.5 % of the worldwide population, more frequently in patients with multiple sclerosis, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease and vitiligo. The most common associations between autoimmune diseases define two clusters: the multiple autoimmune syndromes and overlap syndromes. This review highlights the importance of multiple antibody assays in the diagnosis of multiple autoimmune and overlap syndromes and summarizes the general conditions of autoantibody detection using the model of the five W's: why, who, what, when and where. These conditions represent a new challenge for clinical and laboratory autoimmunologists, who, in a multidisciplinary arena, cooperate in investigating and treating multiple autoimmune disorders.

AB - In the last 15 years, the estimated prevalence of autoimmune diseases increased from about 4 to 9.4 %. Autoimmune co-morbidity (i.e., the association between two or more autoimmune diseases in the same patient) is present in 0.4-0.5 % of the worldwide population, more frequently in patients with multiple sclerosis, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease and vitiligo. The most common associations between autoimmune diseases define two clusters: the multiple autoimmune syndromes and overlap syndromes. This review highlights the importance of multiple antibody assays in the diagnosis of multiple autoimmune and overlap syndromes and summarizes the general conditions of autoantibody detection using the model of the five W's: why, who, what, when and where. These conditions represent a new challenge for clinical and laboratory autoimmunologists, who, in a multidisciplinary arena, cooperate in investigating and treating multiple autoimmune disorders.

KW - Autoimmune liver diseases

KW - Autoimmunology

KW - Co-morbidity

KW - Connective tissue diseases

KW - Multiple autoimmune syndromes

KW - Overlap syndromes

KW - Polyautoimmunity

UR - http://www.scopus.com/inward/record.url?scp=84879556321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879556321&partnerID=8YFLogxK

U2 - 10.1007/s12026-013-8418-7

DO - 10.1007/s12026-013-8418-7

M3 - Article

C2 - 23606120

AN - SCOPUS:84879556321

VL - 56

SP - 425

EP - 431

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 2-3

ER -